Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 6Phase 3 5Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 17Terminated 4Recruiting 3Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Non-Malignant Neoplasm 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hematopoietic and Lymphoid System Neoplasm 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Stem Cell Transplantation × Clear all
NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
36 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
25 enrolled

Hematopoietic and Lymphoid System Neoplasm

NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡